
Company Name
|
|
Kringle Pharma, Inc. |
Established
|
|
December 21, 2001 |
Capital
|
|
100 million yen (as of September 2010) |
Audit Corporation
|
|
KPMG AZSA&Co. |
Main Banks
|
|
Mizuho Bank, Ltd., The Bank of Tokyo-Mitsubishi UFJ, Ltd. |
Major Stockholders
|
|
Nissay Capital Co., Ltd.,
Nippon Life Insurance Company,
Nippon Venture Capital Co., Ltd.,
SBI Investment Co., Ltd.,
Nippon Zenyaku Kogyo, Co., Ltd.,
Inspire Corporation,
MU Hands-on Capital Ltd.,
Bio-Sight Capital Co., Ltd.,
Ant Capital Partners Co., Ltd.
|
Number of Employees (Including Board Members)
|
|
22 (as of December 2010) |
Company Mission
|
|
Our company mission is to save the patients suffering from cancer and incurable diseases by offering a new method of treatment derived from the innovative research and development of HGF and NK4.
|
Main Project
|
|
Research & development of HGF (pharmaceuticals for regenerative medicine) |
|
|
Research & development of NK4 (pharmaceuticals for cancer therapy) |
Access |
|
|
|